Group 1: Medical Devices Industry - The cardiovascular medical device industry has significant growth potential, with the market for cardiac electrophysiology devices in China expected to grow from CNY 65.80 billion in 2021 to CNY 157.26 billion by 2025, and further to CNY 419.73 billion by 2032 [5][6] - The global market for cardiac rhythm management devices increased from USD 9.7 billion in 2016 to USD 10.6 billion in 2021, with a projected growth to USD 12.8 billion by 2030 [5] - The market for coronary artery disease devices in China is also expanding, with the number of patients expected to reach 31.67 million by 2030, and the market for aortic stent grafts projected to grow significantly [6][7] Group 2: AI Cooling Industry - The AI computing upgrade is driving innovation in cooling technologies, with liquid cooling expected to reduce data center energy consumption by 20%-30%, achieving a PUE below 1.2 [8][9] - The liquid cooling market in China is projected to reach USD 1.26 billion in the first half of 2024, with cold plate solutions currently dominating the market due to their maturity and lower infrastructure modification requirements [9][10] - The market for immersion cooling fluids is expected to grow, with silicone oil and fluorinated liquids being key players, although regulatory challenges may arise [10] Group 3: Semiconductor Industry - Aojie Technology (688220.SH) is a leading player in the baseband chip market, with projected revenues of CNY 45.80 billion, CNY 57.35 billion, and CNY 70.72 billion for 2025, 2026, and 2027 respectively [12][13] - The company has a strong presence in both mobile baseband and IoT sectors, with significant growth expected in its ASIC business, which is anticipated to see multiple-fold growth by 2026 [12][14] Group 4: Pharmaceutical Industry - Lifang Pharmaceutical (003020.SZ) is expected to achieve revenues of CNY 18.53 billion, CNY 22.93 billion, and CNY 27.37 billion from 2025 to 2027, with a strong growth trajectory driven by its unique traditional Chinese medicine products [16][17] - The company is set to launch its first generic version of methylphenidate extended-release tablets in April 2025, targeting a large ADHD market in China [17] Group 5: Beverage Industry - IFBH (6603.HK) is positioned to capture a significant share of the coconut water market in China, which is expected to grow at a CAGR of 55% from 2019 to 2025 [19][20] - The company has established a strong brand presence and is leveraging its supply chain advantages to maintain a competitive edge in the market [20] Group 6: Nonferrous Metals Industry - Zhongmin Resources (002738.SZ) is projected to achieve net profits of CNY 6.03 billion, CNY 12.72 billion, and CNY 22.64 billion from 2025 to 2027, driven by its high-margin cesium and rubidium salt business [22][23] - The company is strategically expanding its copper business, which is expected to provide significant growth potential as demand for copper increases [23][24] Group 7: Aerospace Industry - The commercial aerospace sector is anticipated to reach a turning point with increased satellite launches and the development of reusable rockets, which are critical for the growth of satellite internet [29][30] - Companies like Blue Arrow Aerospace and Tianbing Technology are making significant advancements in rocket technology, with planned launches that could enhance China's capabilities in commercial space [30][31]

Investment Rating - The industry investment rating is "Overweight" [4] Core Insights - The cardiovascular medical device market, particularly for arrhythmia-related devices, is substantial, with the Chinese market for cardiac electrophysiology devices expected to grow from 6.58 billion RMB in 2021 to 15.73 billion RMB by 2025, and further to 41.97 billion RMB by 2032 [15][18] - The global market for cardiac rhythm management devices has seen a compound annual growth rate (CAGR) of 1.8% from 2016 to 2021, with expectations to reach 12.8 billion USD by 2030 [19] - The aortic stent market in China is also expanding, with the number of aortic interventions projected to increase significantly by 2030 [28] Summary by Sections 1. Cardiovascular Disease Market Outlook - Cardiovascular diseases are a leading cause of death globally, with a significant increase in intervention procedures expected due to rising health awareness and government policies promoting domestic products [13][14] - The Chinese market for cardiac electrophysiology devices is projected to grow at a CAGR of 24.34% from 2021 to 2025 [15] 2. Arrhythmia Market - The market for cardiac electrophysiology devices in China reached 6.58 billion RMB in 2021, with expectations to grow to 15.73 billion RMB by 2025 [15] - The global cardiac electrophysiology market is expected to reach 32.45 billion USD by 2032, with a CAGR of 12.21% from 2025 to 2032 [18] 3. Coronary Artery Disease Market - The number of patients with coronary artery disease in China is projected to reach 31.67 million by 2030, with a CAGR of 2.0% from 2026 to 2030 [24] - The market for coronary artery interventions is expected to grow significantly, driven by increasing patient numbers and intervention rates [24] 4. Aortic Stent Market - The aortic stent market in China was valued at 2.4 billion RMB in 2021, with projections to reach 4.31 billion RMB by 2030 [28] - The number of aortic interventions is expected to increase to 180,400 by 2030, indicating strong growth potential in this segment [28] 5. Heart Valve Market - The market for transcatheter aortic valve replacement (TAVR) in China is expected to grow from 911.5 million RMB in 2021 to 4.86 billion RMB by 2025, with a CAGR of 52.0% [35] - The number of transcatheter mitral valve interventions is projected to increase significantly, indicating a growing market for heart valve treatments [38][41] 6. Key Companies to Watch - Microelectrophysiology (688351.SH) is highlighted as a leading manufacturer in the cardiac electrophysiology sector [3] - Bairen Medical (688198.SH) is recognized for its excellence in surgical and interventional valve products [3] - Jianxi Technology (09877.HK) is noted for its advancements in transcatheter valve technologies [3]

Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9877） 於二零二五年十月十五日舉行的 二零二五年第二次股東特別大會代表委任表格 | 與本代表委任表格相關的 | 非上市股份 | | --- | --- | | （附註1） 股份數目 | H股 | 本人╱吾等 （附註2） （姓名） | 地址為 | （地址） | | | --- | --- | --- | | 為寧波健世科技股份有限公司（「本公司」） | （附註3） | 股非上市股份╱H股 | | （附註4） 的登記持有人，茲委任大會主席 或 | （姓名） | | | 地址為 | | （地址） | 為本人╱吾等的代表，代表本人╱吾等出席本公司將於二零二五年十月十五日（星期三）下午二時正於中華人民共和國（「中 國」）浙江省寧波 市杭州灣新區濱海四路777號B區5號 樓3樓會議室舉行的二零二五年第二次股東特別大會（「股東特別大會」）及其任何續會，以考慮並酌情 通過股東特別大會通告所載的決議案，並於股東特別大會（及其任何續會）上代表本人╱吾等以本人╱吾等的名義就下列決議案投票 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 通 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 二零二五年第二次股東特別大會通告 茲通告 寧波健世科技股份有限公司（「本公司」）謹訂於二零二五年十月十五日 （星 期 三）下午二時正於中國浙江省寧波市杭州灣新區濱海四路777號B區5號 樓 3樓會議室舉行二零二五年第二次股東特別大會（「股東特別大會」），以 處 理 下 列 事 宜： 特別決議案 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 – 1 – A. 審 議 並 批 准 本 公 司 根 據 市 況 及 本 公 司 需 求，授 予 董 事 會 以 本 決 議 案 所 載 明條款及條件為限之一般授權（「發行授權」），僅 用 於 公 司 發 行 可 轉 換 債 券 以及之後根據可轉換債券要求發行的額外 ...

此乃要件 請即處理 閣下如對本通函有任何疑問，應諮詢 閣下的股票經紀、其他註冊證券交易商、銀行經理、律師、 專業會計師或其他專業顧問。 閣下如已 將名下的 寧波健世科技股份有限公司 股份全部 售出或轉讓，應立即將本通函連同隨 附的代表委任表格送交買主或承讓人，或經手買賣或轉讓的銀行、股票經紀或其他代理商，以 便轉交買主或承讓人。 (2)二零二五年第二次股東特別大會通告 本封面頁所用詞彙具有本通函所界定的相同涵義。 寧波健世科技股份有限公司謹訂於二零二五年十月十五日（星期三）下午二時正於中國浙江省 寧波市杭州灣新區濱海四路777號B區5號 樓3樓 會 議 室 舉 行 股 東 特 別 大 會，召 開 大 會 的 通 告 載 於本通函第EGM-1至EGM-5頁。 本 通 函 亦 隨 附 股 東 特 別 大 會 適 用 代 表 委 任 表 格。該 代 表 委 任 表 格 亦 刊 載 於 聯 交 所 網 站 (https://www.hkexnews.hk)及本公司網站(https://www.jenscare.com)。倘 閣下無法出席股東 特 別 大 會，務 請 將 代 表 委 任 表 格 按 其 上 列 印 的 ...

寧波健世科技股份有限公司 Jenscare Scientic Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） 股份代號 : 9877 2025 中期報告 寧波健世科技股份有限公司 Jenscare Scientific Co., Ltd. 中期報告 Interim Report 2025 目錄 2 釋義 5 公司資料 7 財務摘要 8 業務摘要 11 管理層討論及分析 25 其他資料 36 中期簡明綜合損益及其他全面收益表 37 中期簡明綜合財務狀況表 38 中期簡明綜合權益變動表 39 中期簡明綜合現金流量表 41 中期簡明綜合財務資料附註 2 2025年中期報告 寧波健世科技股份有限公司 | 「組織章程細則」 | 指 | 本公司組織章程細則（經不時修訂） | | --- | --- | --- | | 「審核委員會」 | 指 | 董事會審核委員會 | | 「董事會」 | 指 | 董事會 | | 「監事會」 | 指 | 監事會 | | 「CE認證」 | 指 | Conformité Européenne，即標示於歐洲經濟區(EEA)內所售產品符合健 | | | | 康、安全及環保標準的管理標 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 寧波健世科技股份有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 310,306,209 | RMB | | 1 RMB | | 310,306,209 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 310,306,209 | RMB | | 1 RMB | | 310,306,209 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請 ...

Group 1 - The company reported a total revenue of RMB 25.5 million for the six months ending June 30, 2025, with a primary revenue of RMB 13.4 million and other income of RMB 12.1 million [1] - The adjusted loss for the period was RMB 91.8 million, a decrease of RMB 2.4 million compared to the previous year's loss of RMB 94.2 million, attributed to revenue growth and improved operational efficiency [1] - Research and development expenses increased from RMB 82.2 million in the previous year to RMB 88.9 million during the reporting period, primarily due to a rise in share-based payment expenses from RMB 11.7 million to RMB 36.2 million [1] Group 2 - The company's vision is to become a high-potential medical device enterprise with a global perspective, providing innovative products for the treatment of structural heart diseases [2] - The company plans to accelerate the global business layout and progress of the LuX-Valve product series, aiming to become a benchmark in the transcatheter tricuspid valve replacement field [2] - The company aims to enhance operational efficiency, accelerate revenue and profit growth, and continuously innovate to achieve sustainable development of its long-term international strategy [2]

Core Insights - The company reported interim results for the six months ending June 30, 2025, achieving revenue of 13.426 million RMB, compared to no revenue in the same period last year [1] - Gross profit for the period was 11.827 million RMB, also compared to no gross profit in the previous year [1] - Research and development expenses amounted to 88.885 million RMB [1] Revenue Drivers - The revenue growth is primarily attributed to the commercialization of the company's interventional products for treating structural heart diseases, leading to an increase in sales volume [1] Product Development - In the first half of 2025, the company made significant progress in its product pipeline for treating tricuspid, aortic, and mitral valve diseases, resulting in a diversified and high-potential product portfolio [1] International Expansion - The company is actively enhancing its international business layout to increase product influence and clinical application scale, laying a solid foundation for long-term high-speed growth [1]

Core Viewpoint - The company reported significant revenue growth and advancements in its product pipeline for the treatment of structural heart diseases, indicating a strong foundation for future growth [1]. Financial Performance - The company achieved revenue of 13.426 million RMB for the six months ending June 30, 2025, compared to no revenue in the same period last year [1]. - Gross profit reached 11.827 million RMB, also showing an increase from zero in the previous year [1]. - Research and development expenses amounted to 88.885 million RMB [1]. Product Development - The company made substantial progress in its product pipeline for treating tricuspid, aortic, and mitral valve diseases, resulting in a diversified and high-potential product portfolio [1]. - The commercialization of interventional products for treating structural heart diseases has been a key driver of revenue growth [1]. Strategic Initiatives - The company is intensifying its international business expansion efforts to enhance product influence and clinical application scale, laying a solid foundation for long-term high-speed growth [1].